TELA Bio (TELA) vs Xtant Medical (XTNT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
TELA Bio (TELA) has outperformed Xtant Medical (XTNT) over the past year, losing 41.2% versus a loss of 66.1%. Over five years, XTNT leads with a -73.1% price change compared with -94.4% for TELA. TELA Bio is the larger company by market cap ($31.1 million vs $29.5 million), about 1.1 times the size.
Xtant Medical converts more of its revenue into profit, with a net margin of 3.7% versus -48.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | TELA | XTNT |
|---|---|---|
| Share price | $0.6885 | $0.21 |
| Market cap | $31.11M | $29.49M |
| 1-day change | -5.27% | -2.82% |
| YTD return | -41.65% | -73.08% |
| 1-year return | -41.15% | -66.13% |
| 5-year return | -94.37% | -73.08% |
| EPS (TTM) | $-0.74 | $-0.11 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $80.28M | $133.93M |
| Revenue growth (YoY) | +15.84% | +14.21% |
| Net income (latest FY) | $-38.83M | $4.97M |
| Gross margin | 67.69% | 62.92% |
| Operating margin | -42.05% | 5.44% |
| Net margin | -48.37% | 3.71% |
| 52-week high | $1.50 | $0.84 |
| 52-week low | $0.501 | $0.17 |
| Distance from 52-week high | -54.10% | -75.00% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +202.11% | +390.48% |
| Average volume | 217.44K | 1.69M |
| Shares outstanding | 45.19M | 140.45M |
| Employees | 218 | 151 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TELA has outperformed XTNT by 25.0 percentage points over the past year.
- Xtant Medical is more profitable, keeping 3.7 cents of every revenue dollar as net income versus -48.4 cents for TELA Bio.
About TELA Bio
TELA stock →TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene, polyglycolic acid, and polylactic-co-glycolic acid designed to be used in laparoscopic and robotic-assisted hernia surgical repairs.
Health Care · Medical/Dental Instruments · 218 employees
About Xtant Medical
XTNT stock →Xtant Medical Holdings, Inc. provides regenerative medicine products and medical devices for orthopedic and neurological surgeons in the United States and internationally.
Health Care · Medical/Dental Instruments · 151 employees
TELA vs XTNT FAQ
Which is bigger, TELA Bio or Xtant Medical?
TELA Bio (TELA) is larger, with a market capitalization of $31.11M compared with $29.49M for Xtant Medical (XTNT).
Which stock has performed better over the past year, TELA or XTNT?
TELA returned -41.15% over the past 12 months, compared with -66.13% for XTNT (price return, excluding dividends). Past performance does not predict future results.
Are TELA Bio and Xtant Medical in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.